NCT07524452招募中3 期
A Phase III Study of Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma： a Multicenter, Randomized Controlled Trial
Ming-Yuan Chen1 个研究点 分布在 1 个国家目标入组 430 人开始时间: 2026年2月6日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 430
- 试验地点
- 1
- 主要终点
- Event-Free Survival Rate (EFS)
研究概览
简要总结
This study is a randomized, open-label, multicenter phase III trial designed to systematically evaluate the efficacy and safety of perioperative neoadjuvant and adjuvant therapy with Becotatug vedotin in combination with PD-1 inhibitor versus PD-1 inhibitor alone in patients with EGFR-positive, CPS ≥ 1 resectable locally advanced head and neck squamous cell carcinoma .
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily sign the informed consent form;
- •Untreated, histologically confirmed head and neck squamous cell carcinoma (oral cavity, oropharynx, hypopharynx, or larynx), EGFR-positive, CPS ≥ 1, with clinical stage (AJCC 8th edition): p16-positive oropharynx: Stage III (T4N0-2M0); p16-negative oropharynx: Stage III or IVA; larynx/hypopharynx/oral cavity: Stage III or IVA;
- •Eligible for curative-intent surgery as determined by the surgeon;
- •Age: 18 to 75 years;
- •ECOG performance status 0-1;
- •Life expectancy greater than 6 months;
- •At least one measurable lesion per RECIST 1.1;
- •Adequate organ function, based on meeting all of the following criteria (no receipt of blood components or hematopoietic growth factors within 14 days prior to testing): hemoglobin ≥ 90 g/L; absolute neutrophil count ≥ 1.5 × 10⁹/L; platelet count ≥ 100 × 10⁹/L; serum albumin ≥ 28 g/L; total bilirubin ≤ 1.5 × upper limit of normal (ULN); ALT and AST ≤ 2.5 × ULN; serum creatinine ≤ 1.5 × ULN, with creatinine clearance ≥ 50 mL/min; activated partial thromboplastin time and international normalized ratio (INR) ≤ 1.5 × ULN (patients receiving a stable dose of anticoagulant therapy, such as low molecular weight heparin or warfarin, may be enrolled if INR is within the expected therapeutic range for the anticoagulant). Thyroid-stimulating hormone (TSH) ≤ ULN; if abnormal, T3 and T4 levels should be assessed, and patients with normal T3 and T4 levels may be enrolled;
- •Baseline left ventricular ejection fraction (LVEF) ≥ 50% as measured by multigated acquisition (MUGA) scan or echocardiography (ECHO);
- •Women of childbearing potential must agree to use contraception (e.g., intrauterine device, contraceptive pill, or condom) during the treatment period and for 3 months after the last dose;
- •Good compliance.
排除标准
- •Pregnant or breastfeeding women.
- •History of allergy to PD-1 inhibitors.
- •History of other malignancies within the past 5 years or at enrollment, with the exception of cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and thyroid papillary tumors.
- •Residual toxicity from prior anti-tumor therapy (including immunotherapy, targeted therapy, chemotherapy, or radiotherapy, etc.) other than alopecia, fatigue, and grade 2 hypothyroidism, or clinically significant laboratory abnormalities greater than grade 1 (CTCAE v5.0).
- •Uncontrolled cardiac conditions or diseases, such as: ① NYHA Class II or greater heart failure, ② unstable angina, ③ myocardial infarction within 1 year, and ④ patients with clinically significant ventricular arrhythmias requiring intervention.
- •Grade ≥ 2 peripheral neuropathy (per CTCAE v5.0).
- •Pulmonary embolism or deep vein thrombosis within 3 months prior to enrollment (excluding catheter-related thrombosis from infusion ports or PICC lines).
- •Active bleeding, history of coagulation disorders, or patients receiving coumarin anticoagulant therapy.
- •Known hypersensitivity to any component or excipient of vibecotamab (citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, sodium chloride, and polysorbate 80), or known grade ≥ 3 hypersensitivity reaction to other prior anti-EGFR agents (including investigational drugs) or other monoclonal antibodies.
- •Receipt of any of the following treatments:
- •① Any investigational drug prior to the first dose of the current study drug.
- •② Concurrent participation in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period.
- •③ Use of systemic corticosteroids (more than 10 mg of prednisone or equivalent per day) or other immunosuppressive agents within 2 weeks prior to the first dose of study drug, except for the use of corticosteroids for localized inflammation, prevention of allergies, or nausea and vomiting. In the absence of active autoimmune disease, inhaled or topical steroids and adrenal corticosteroid replacement doses greater than 10 mg prednisone equivalent per day are permitted.
- •④ Administration of live vaccines within 4 weeks prior to the first dose of study drug.
- •⑤ Major surgery or severe trauma within 4 weeks prior to the first dose of study drug.
- •Severe infection (greater than grade 2 per CTCAE), such as severe pneumonia requiring hospitalization, bacteremia, or infectious complications, occurring within 4 weeks prior to the first dose of study drug; baseline chest imaging indicating active pulmonary inflammation or signs and symptoms of infection within 2 weeks prior to the first dose of study drug, or indicating the need for oral or intravenous antibiotic therapy (excluding prophylactic antibiotic use).
- •History of or concurrent severe chronic obstructive pulmonary disease with respiratory failure, severe pulmonary insufficiency, symptomatic bronchospasm, etc.
- •History of active autoimmune diseases or syndromes (including but not limited to interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism). Patients with vitiligo that did not require any intervention in adulthood, or childhood asthma/allergy that has resolved, are not excluded.
- •History of immunodeficiency, including HIV-positive status or other acquired/congenital immunodeficiency diseases, or history of organ transplantation or bone marrow transplantation.
- •Patients with active tuberculosis infection by history or CT findings, or history of active tuberculosis infection within 1 year prior to enrollment, or history of active tuberculosis infection more than 1 year prior without receiving formal treatment.
- •Active hepatitis B (HBV DNA ≥ 2,000 IU/mL or 10,000 copies/mL) or hepatitis C (positive HCV antibody test with HCV RNA above the lower limit of detection).
- •Uncontrolled pleural, peritoneal, pelvic, or pericardial effusion requiring drainage ≥ 1 time per month.
- •Known history of substance abuse, alcoholism, or drug use.
- •Inappropriate for inclusion based on the investigator's judgment.
研究组 & 干预措施
Becotatug vedotin plus pucotenlimab arm
Experimental
Patients receive Becotatug vedotin combined with pucotenlimab as neoadjuvant treatment prior to surgical resection and as adjuvant treatment after radiotherapy.
干预措施: Neoadjuvant and Adjuvant Becotatug Vedotin (Drug)
Becotatug vedotin plus pucotenlimab arm
Experimental
Patients receive Becotatug vedotin combined with pucotenlimab as neoadjuvant treatment prior to surgical resection and as adjuvant treatment after radiotherapy.
干预措施: Neoadjuvant and Adjuvant Immunotherapy (Drug)
Becotatug vedotin plus pucotenlimab arm
Experimental
Patients receive Becotatug vedotin combined with pucotenlimab as neoadjuvant treatment prior to surgical resection and as adjuvant treatment after radiotherapy.
干预措施: Surgery (Procedure)
Becotatug vedotin plus pucotenlimab arm
Experimental
Patients receive Becotatug vedotin combined with pucotenlimab as neoadjuvant treatment prior to surgical resection and as adjuvant treatment after radiotherapy.
干预措施: Adjuvant Radiotherapy (Radiation)
pucotenlimab arm
Active Comparator
Patients receive pucotenlimab as neoadjuvant treatment prior to surgical resection and as adjuvant duiring and after radiotherapy.
干预措施: Neoadjuvant and Adjuvant Immunotherapy (Drug)
pucotenlimab arm
Active Comparator
Patients receive pucotenlimab as neoadjuvant treatment prior to surgical resection and as adjuvant duiring and after radiotherapy.
干预措施: Surgery (Procedure)
pucotenlimab arm
Active Comparator
Patients receive pucotenlimab as neoadjuvant treatment prior to surgical resection and as adjuvant duiring and after radiotherapy.
干预措施: Adjuvant Radiotherapy (Radiation)
pucotenlimab arm
Active Comparator
Patients receive pucotenlimab as neoadjuvant treatment prior to surgical resection and as adjuvant duiring and after radiotherapy.
干预措施: Adjuvant Cisplatin (Drug)
Becotatug vedotin plus pucotenlimab arm
Experimental
Patients receive Becotatug vedotin combined with pucotenlimab as neoadjuvant treatment prior to surgical resection and as adjuvant treatment after radiotherapy.
干预措施: Adjuvant Cisplatin (Drug)
结局指标
主要结局
Event-Free Survival Rate (EFS)
时间窗: 3 years
Defined as the time from randomization to the first occurrence of disease progression, relapse, or death from any cause.
次要结局
- Overall Survival (OS)(3 years)
- Distant Metastasis-Free Survival (DMFS)(3 years)
- Locoregional Relapse-Free Survival (LRRFS)(3 years)
- Objective Response Rate (ORR)(After the completion of neoadjuvant therapy, prior to surgery.)
- Disease Control Rate (DCR)(After the completion of neoadjuvant therapy, prior to surgery.)
- Major Pathologic Response Rate (mPR):(1 week post-surgery)
- Pathologic Complete Response Rate (pCR)(1 week post-surgery)
- Incidence of treatment related acute complications(up to 1 year)
- Incidence of treatment related late complications(up to 3 years)
- Non-Surgery Delay Rate(8 weeks after two cycles of neoadjuvant therapy)
- R0 Resection Rate(1 week post-surgery.)
- General Quality of Life(Baseline, week 4 (post-neoadjuvant), week 6 (preoperative), week 8 (postoperative), week 10 (pre-radiotherapy), week 17 (post-radiotherapy), every 2 cycles of adjuvant therapy (each cycle is 21 days), and at each follow-up, up to 3 years)
- Head and Neck Cancer-Specific Quality of Life(Baseline, week 4 (post-neoadjuvant), week 6 (preoperative), week 8 (postoperative), week 10 (pre-radiotherapy), week 17 (post-radiotherapy), every 2 cycles of adjuvant therapy (each cycle is 21 days), and at each follow-up, up to 3 years.)
研究者
Ming-Yuan Chen
Professor, Chief physician
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell CarcinomaNCT07381075West China Hospital90
尚未招募
2 期
MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical TrialNCT07381699West China Hospital30
招募中
2 期
A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal CancerNCT07424664Union Hospital, Tongji Medical College, Huazhong University of Science and Technology30
尚未招募
3 期
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non small Cell Lung Cancer With High Levels of PDL1.CTRI/2025/07/091069Pfizer Inc.714
招募中
3 期
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCNCT07459296First Affiliated Hospital of Guangxi Medical University266